在复发性/耐药性扩散性大B细胞淋巴瘤中,根据治疗线路的实际护理总成本
Justin Gatwood1, Anthony Masaquel2, David Fox2
1College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, USA.
Journal of medical economics
|April 30, 2024
概括
复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 的总医疗费用随着每一额外的治疗线增加. 改善最初的治疗方法可以减少DLBCL的经济负担.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
- 现实世界的证据.
背景情况:
- 复发性/耐药性 (R/R) 扩散性大B细胞淋巴瘤 (DLBCL) 由于多种新疗法和缺乏明确的护理标准而面临挑战.
- 之前对治疗线路 (LoTs) 的总护理成本 (TCC) 的评估需要根据最新的现实数据进行更新.
研究的目的:
- 根据LOT的数量来评估R/R DLBCL疗法的现实世界TCC.
- 分析R/R DLBCL患者在不同LoT的医疗保健资源利用率和成本.
主要方法:
- 利用IQVIA PharMetrics Plus数据库 (2015-2021) 对美国18岁以上的患者,接受一线修复药加环胺,多克索鲁比辛,温克里斯和普雷尼松 (R-CHOP) 或类似的治疗.
- 包括310名接受二线或后一线治疗的患者;通过LoT评估成本,并对COVID-19影响进行敏感性分析.
主要成果:
- 平均TCC每个患者每月增加每一个LoT:$ 40,604 (2线),$ 48,630 (3线),和$ 59,499 (4线).
- 住院费用占TCC的最大部分,其次是门诊和药房费用.
- 敏感性分析证实结果没有受到COVID-19大流行的影响.
结论:
- 在R/R DLBCL中,总医疗费用随着每次后续的治疗线路显著升级.
- 加强一线治疗以最大限度地减少对额外治疗线的需求,可以大幅减少DLBCL的整体经济负担.
关键词:
在这里,我们可以看到C C C C C二氧化碳 (C02) 是一个C1 一个人的心态C14 C14 是一个扩散大的B细胞淋巴瘤.这就是IQVIA的IQVIA.在R-切片.经过成本分析,分析成本.现实世界的真实世界.耐火材料 耐火材料 耐火材料这是一个复发的复发.更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...